MAOB and Parkinson disease: The existing pharmacopeia for PD—spanning from the mainstay levodopa to a suite of dopamine agonists, COMT inhibitors, anticholinergics, MAO-B inhibitors, amantadine, safinamide, istradefylline, and pimavanserin—offers symptomatic respite but falls short of halting disease progression (Armstrong and Okun, 2020; Jankovic and Tan, 2020).